SG11201408318RA - Compositions and methods for transmucosal absorption - Google Patents
Compositions and methods for transmucosal absorptionInfo
- Publication number
- SG11201408318RA SG11201408318RA SG11201408318RA SG11201408318RA SG11201408318RA SG 11201408318R A SG11201408318R A SG 11201408318RA SG 11201408318R A SG11201408318R A SG 11201408318RA SG 11201408318R A SG11201408318R A SG 11201408318RA SG 11201408318R A SG11201408318R A SG 11201408318RA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- new york
- international
- methods
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000010521 absorption reaction Methods 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 abstract 1
- 239000002610 basifying agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 abstract 1
- 229960003572 cyclobenzaprine Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261660593P | 2012-06-15 | 2012-06-15 | |
| US201261667774P | 2012-07-03 | 2012-07-03 | |
| US201261725402P | 2012-11-12 | 2012-11-12 | |
| US201361792900P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/046023 WO2013188847A1 (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408318RA true SG11201408318RA (en) | 2015-01-29 |
Family
ID=49758769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408318RA SG11201408318RA (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
| SG10201605407TA SG10201605407TA (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201605407TA SG10201605407TA (en) | 2012-06-15 | 2013-06-14 | Compositions and methods for transmucosal absorption |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20140171515A1 (enExample) |
| EP (1) | EP2861223B1 (enExample) |
| JP (5) | JP6259452B2 (enExample) |
| CN (2) | CN111388430A (enExample) |
| AR (1) | AR092330A1 (enExample) |
| AU (2) | AU2013274003B2 (enExample) |
| BR (1) | BR112014031394B1 (enExample) |
| CA (2) | CA2876902C (enExample) |
| DK (1) | DK2861223T3 (enExample) |
| ES (1) | ES2929133T3 (enExample) |
| HR (1) | HRP20221325T1 (enExample) |
| HU (1) | HUE060175T2 (enExample) |
| IL (1) | IL236268B (enExample) |
| LT (1) | LT2861223T (enExample) |
| MX (2) | MX2021005317A (enExample) |
| MY (1) | MY194495A (enExample) |
| NZ (2) | NZ631144A (enExample) |
| PL (1) | PL2861223T3 (enExample) |
| PT (1) | PT2861223T (enExample) |
| RS (1) | RS63822B1 (enExample) |
| SG (2) | SG11201408318RA (enExample) |
| SI (1) | SI2861223T1 (enExample) |
| SM (1) | SMT202200436T1 (enExample) |
| TW (3) | TWI683660B (enExample) |
| WO (1) | WO2013188847A1 (enExample) |
| ZA (1) | ZA201500288B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037281T2 (hu) | 2009-11-20 | 2018-08-28 | Tonix Pharma Holdings Ltd | Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával |
| US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
| ES2769879T3 (es) | 2013-03-15 | 2020-06-29 | Tonix Pharma Holdings Ltd | Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol |
| CN107072968B (zh) | 2014-09-18 | 2021-01-12 | 通尼克斯制药控股有限公司 | 环苯扎林盐酸盐的低共熔混合物配制剂 |
| CN108024976A (zh) * | 2015-07-15 | 2018-05-11 | 特兰埃克斯公司 | 阿米替林用于阻断大脑半通道的用途和用于增强其体内作用的方法 |
| US12337063B2 (en) * | 2016-09-02 | 2025-06-24 | University Of Sharjah | Formulation for atropine sulfate rapidly-disintegrating sublingual tablets |
| WO2019014651A1 (en) | 2017-07-13 | 2019-01-17 | Tonix Pharmaceuticals Holding Corp. | ANALOGUES OF CYCLOBENZAPRINE AND AMITRYPTILENE |
| CN107496355B (zh) * | 2017-08-24 | 2021-04-30 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下喷雾剂及其制备方法 |
| CN107519142B (zh) * | 2017-08-24 | 2021-02-26 | 正大制药（青岛）有限公司 | 一种盐酸环苯扎林舌下片及其制备方法 |
| IL275144B2 (en) * | 2017-12-08 | 2024-12-01 | Hoffmann La Roche | Pharmaceutical formulation |
| MX2020006140A (es) | 2017-12-11 | 2020-08-13 | Tonix Pharma Holdings Ltd | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. |
| CN108721240A (zh) * | 2018-06-08 | 2018-11-02 | 华益药业科技(安徽)有限公司 | 一种25mg阿米替林薄膜包衣片处方和工艺规程 |
| JP7691739B2 (ja) * | 2018-08-20 | 2025-06-12 | トニックス ファーマ ホールディングス リミテッド | 急性ストレス障害および外傷後ストレス障害を処置する方法 |
| US20220339124A1 (en) * | 2019-09-30 | 2022-10-27 | Cadila Healthcare Limited | Intranasal pharmaceutical compositions of cyclobenzaprine |
| US20210315841A1 (en) * | 2020-04-08 | 2021-10-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for sexual dysfunction |
| MX2023005899A (es) | 2020-11-20 | 2023-08-16 | TONIX Pharmaceuticals Holding Corp | Tratamiento con ciclobenzaprina para el trastorno por consumo de alcohol. |
| MX2023006720A (es) | 2020-12-07 | 2023-08-18 | TONIX Pharmaceuticals Holding Corp | Tratamiento con ciclobenzaprina para fibromialgia. |
| WO2022170107A2 (en) | 2021-02-04 | 2022-08-11 | Tonix Pharmaceuticals Holding Corp. | An improved method of assessing clinical response in the treatment of ptsd symptoms |
| EP4412602A1 (en) | 2021-10-06 | 2024-08-14 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients |
| JP2025519847A (ja) | 2022-06-21 | 2025-06-26 | トニックス ファーマシューティカルズ ホールディング コーポレイション | （ＳＡＲＳ）－ＣｏＶ－２感染症の急性期後後遺症（ＰＡＳＣ）のためのシクロベンザプリン処置 |
| WO2025160302A1 (en) | 2024-01-25 | 2025-07-31 | Tonix Pharmaceuticals Holding Corp. | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| WO1999018937A1 (en) * | 1997-10-16 | 1999-04-22 | Merck & Co., Inc. | New cyclobenzaprine composition |
| DE69904465T2 (de) * | 1998-05-14 | 2003-10-02 | Alza Corp., Mountain View | Therapie von depressionen |
| AR025110A1 (es) | 1999-08-13 | 2002-11-06 | Vela Pharmaceuticals Inc | Metodos y composiciones para tratar o prevenir alteraciones del sueno y enfermedades asociadas usando dosis muy bajas de ciclobenzaprina |
| BR0013122A (pt) | 1999-08-13 | 2002-04-30 | Vela Pharmaceuticals Inc | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina |
| AU2001261744A1 (en) * | 2000-05-19 | 2001-12-03 | Npd Llc | Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
| EP1596824A4 (en) * | 2003-02-04 | 2011-11-23 | Chrysalis Tech Inc | AEROSOL FORMULATIONS AND AEROSOL DISTRIBUTION OF BUSPIRONE, BUPRENORPHINE, TRIAZOLAM, CYCLOBENZAPRINE AND ZOLPIDEM |
| US20090117054A1 (en) * | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
| JP2009079060A (ja) * | 2008-10-15 | 2009-04-16 | Novadel Pharma Inc | 極性または非極性の、バッカルスプレーまたはカプセル |
| US20100266682A1 (en) * | 2008-12-10 | 2010-10-21 | Nipun Davar | Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same |
| US20100247586A1 (en) * | 2009-03-27 | 2010-09-30 | Andreas Hugerth | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties |
| HUE037281T2 (hu) * | 2009-11-20 | 2018-08-28 | Tonix Pharma Holdings Ltd | Eljárás és készítmény poszt-traumás stressz rendellenesség tüneteinek kezelésére ciklobenzaprin alkalmazásával |
| US20110319389A1 (en) * | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
| ITMI20110558A1 (it) * | 2011-04-06 | 2012-10-07 | Campiglio Consulting Srl | Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale |
| ES2769879T3 (es) * | 2013-03-15 | 2020-06-29 | Tonix Pharma Holdings Ltd | Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol |
-
2013
- 2013-06-14 ES ES13804115T patent/ES2929133T3/es active Active
- 2013-06-14 PL PL13804115.7T patent/PL2861223T3/pl unknown
- 2013-06-14 CN CN202010024102.2A patent/CN111388430A/zh active Pending
- 2013-06-14 TW TW107117266A patent/TWI683660B/zh active
- 2013-06-14 MX MX2021005317A patent/MX2021005317A/es unknown
- 2013-06-14 MX MX2014015436A patent/MX382516B/es unknown
- 2013-06-14 SG SG11201408318RA patent/SG11201408318RA/en unknown
- 2013-06-14 AU AU2013274003A patent/AU2013274003B2/en active Active
- 2013-06-14 US US13/918,692 patent/US20140171515A1/en active Pending
- 2013-06-14 BR BR112014031394-6A patent/BR112014031394B1/pt active IP Right Grant
- 2013-06-14 SM SM20220436T patent/SMT202200436T1/it unknown
- 2013-06-14 LT LTEPPCT/US2013/046023T patent/LT2861223T/lt unknown
- 2013-06-14 MY MYPI2014703784A patent/MY194495A/en unknown
- 2013-06-14 DK DK13804115.7T patent/DK2861223T3/da active
- 2013-06-14 CN CN201380039522.6A patent/CN104684550A/zh active Pending
- 2013-06-14 WO PCT/US2013/046023 patent/WO2013188847A1/en not_active Ceased
- 2013-06-14 HR HRP20221325TT patent/HRP20221325T1/hr unknown
- 2013-06-14 TW TW102121267A patent/TWI590820B/zh active
- 2013-06-14 AR ARP130102101A patent/AR092330A1/es not_active Application Discontinuation
- 2013-06-14 TW TW106117185A patent/TWI642429B/zh active
- 2013-06-14 SG SG10201605407TA patent/SG10201605407TA/en unknown
- 2013-06-14 NZ NZ631144A patent/NZ631144A/en unknown
- 2013-06-14 SI SI201332010T patent/SI2861223T1/sl unknown
- 2013-06-14 PT PT138041157T patent/PT2861223T/pt unknown
- 2013-06-14 NZ NZ726488A patent/NZ726488A/en unknown
- 2013-06-14 CA CA2876902A patent/CA2876902C/en active Active
- 2013-06-14 CA CA3118913A patent/CA3118913C/en active Active
- 2013-06-14 EP EP13804115.7A patent/EP2861223B1/en active Active
- 2013-06-14 HU HUE13804115A patent/HUE060175T2/hu unknown
- 2013-06-14 JP JP2015517469A patent/JP6259452B2/ja active Active
- 2013-06-14 RS RS20221005A patent/RS63822B1/sr unknown
-
2014
- 2014-12-15 IL IL236268A patent/IL236268B/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00288A patent/ZA201500288B/en unknown
-
2017
- 2017-10-02 JP JP2017192713A patent/JP2017222726A/ja not_active Withdrawn
-
2018
- 2018-10-04 AU AU2018241128A patent/AU2018241128B2/en active Active
-
2019
- 2019-05-14 JP JP2019091262A patent/JP2019123757A/ja not_active Withdrawn
-
2021
- 2021-06-16 JP JP2021100154A patent/JP2021138765A/ja not_active Withdrawn
-
2024
- 2024-02-02 JP JP2024014696A patent/JP2024032964A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201408261UA (en) | Syringe | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201807778YA (en) | Bicyclic compounds for diagnosis and therapy | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201406973PA (en) | Complement pathway modulators and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof |